Alzheimer’s Therapeutics Market Analysis and Segment Forecasts by 2024
www.orbisresearch.com; +1 (214) 884-6817; +9120-64101019
The global alzheimer’s therapeutics market is expected to reach USD 6.4 billion in 2024, according to a new report by Grand View Research. Some primary factors driving the market growth includes rising government initiatives in order to raise awareness levels among people. Growing knowledge about the Alzheimer’s disease (AD) and its high prevalence and incidence in developing economies are few of the major drivers supporting the market growth. Several governments, nonprofit, and private organizations worldwide are actively engaged in increasing people’s awareness regarding progressive AD, such as Alzheimer’s Association, the Alzheimer’s Society of Canada, Alzheimer’s Europe organization, and various other small organizations. Browse the report: http://www.orbisresearch.com/reports/index/alzheimers-therapeutics-marketanalysis-by-drug-class-cholinesterase-inhibitors-nmda-n-methyl-d-aspartate-receptor-antagonist-andsegment-forecasts-to-2024
Furthermore, the increased government funding for providing better care and support to the people with partial dementia is another important factor anticipated to enlarge market growth. For instance, organizations like Florida Department of Health, the National Institute of Health, and Alzheimer’s Association in partnership with other private and government organizations provide funds to the research centers. The presence of various pipeline drugs is anticipated to provide the market with potential growth opportunities. For instance, LMTX by TauRx Pharmaceutical Ltd.; idalopirdine (Lu AE58054) by Lundbeck; crenezumab by AC Immune SA; and BAN2401 by Eisai. Request a sample of the report:http://www.orbisresearch.com/contacts/request-sample/111358 Moreover, novel therapeutics with minimal dosage requirement has been introduced resulting in cost-effective alternatives, which is further expected to boost the market growth. For instance, Namzaric by Actavis was developed in two forms: 10 mg and 28 mg. 10 mg requires to be administered twice a day, while 28 mg requires to be administered once in a day. Further Key Findings from the Study Suggest: The cholinesterase inhibitors segment was dominant in 2013 but lost hold on the market till 2015. Patent expiry of key drugs such as Aricept, Exelon, and Razadyne was the major factor for decline in market share. Exelon transdermal patch is estimated to lose exclusivity in 2019. It is a highly prescribed drug for the treatment of mild to moderate AD, which contributed toward its revenue generation in 2015. Buy the report@ http://www.orbisresearch.com/contact/purchase/111358
www.orbisresearch.com; +1 (214) 884-6817; +9120-64101019
N-methyl-D-aspartate receptor antagonist, on the other hand, is expected to witness a significant growth of around 16.0% over the forecast period owing to introduction of extended relase formulation of Namenda. Other drug therapies such as monocloclonal antibodies and drugs targeting Tau proteins are in being studied in latter phases of the clinical trials. Presence of a strong of pipeline drugs for target disease are attributing toward fastest growth of these drugs North America dominated the overall market in terms of revenue with share of over 33.0% in 2015, which is majorly facilitated by the availability of sophisticated healthcare facilities and infrastructure. Some key players operating in this industry are Pfizer, Inc.; Merck & Co. Inc.; Novartis AG; Eisai Co. Ltd., H. Lundbeck A/S, AC Immune; TauRx Pharmaceuticals Ltd.; Actavis plc.; Forest Laboratories; and Teva Pharmaceuticals Industries Ltd. Market players are expanding their product portfolio by developing and launching generic versions of drugs to sustain its market position. For instance, in 2015, Dr. Reddy’s Laboratories Ltd. and Mylan launched the generic version of Namenda (Forest laboratories – Actavis). About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients. Contact Information: Hector Costello Senior Manager – Client Engagements 4144N Central Expressway, Suite 600, Dallas, Texas – 75204, U.S.A. Phone No.: +1 (214) 884-6817; +9164101019 Email: sales@orbisresearch.com Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research Follow us on Twitter: https://twitter.com/orbisresearch Like us on Facebook: https://www.facebook.com/OrbisResearch
www.orbisresearch.com; +1 (214) 884-6817; +9120-64101019